Aralez Pharmaceuticals Company Profile (NASDAQ:ARLZ)

About Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals logoAralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ARLZ
  • CUSIP: 73941U10
  • Web: www.aralez.com
Capitalization:
  • Market Cap: $94.26 million
  • Outstanding Shares: 66,848,000
Average Prices:
  • 50 Day Moving Avg: $1.74
  • 200 Day Moving Avg: $1.44
  • 52 Week Range: $0.95 - $5.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.36
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: $87.22 million
  • Price / Sales: 1.08
  • Book Value: $1.12 per share
  • Price / Book: 1.26
Profitability:
  • EBITDA: ($55,020,000.00)
  • Net Margins: -122.35%
  • Return on Equity: -90.17%
  • Return on Assets: -22.15%
Debt:
  • Debt-to-Equity Ratio: 3.66%
  • Current Ratio: 1.11%
  • Quick Ratio: 1.04%
Misc:
  • Average Volume: 793,489 shs.
  • Beta: 1.52
  • Short Ratio: 4.84
 

Frequently Asked Questions for Aralez Pharmaceuticals (NASDAQ:ARLZ)

What is Aralez Pharmaceuticals' stock symbol?

Aralez Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARLZ."

How were Aralez Pharmaceuticals' earnings last quarter?

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) posted its earnings results on Wednesday, August, 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.01. The company had revenue of $27.62 million for the quarter, compared to analyst estimates of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The business's quarterly revenue was up 119.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.27) EPS. View Aralez Pharmaceuticals' Earnings History.

When will Aralez Pharmaceuticals make its next earnings announcement?

Aralez Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Aralez Pharmaceuticals.

Where is Aralez Pharmaceuticals' stock going? Where will Aralez Pharmaceuticals' stock price be in 2017?

2 brokers have issued twelve-month price targets for Aralez Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect Aralez Pharmaceuticals' stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Aralez Pharmaceuticals.

Who are some of Aralez Pharmaceuticals' key competitors?

Who are Aralez Pharmaceuticals' key executives?

Aralez Pharmaceuticals' management team includes the folowing people:

  • Arthur S. Kirsch, Independent Chairman of the Board
  • Andrew Ian Koven, President, Chief Business Officer
  • Adrian Adams, Chief Executive Officer, Director
  • Scott J. Charles, Chief Financial Officer, Senior Vice President
  • Jennifer Lou Armstrong, Executive Vice President - Human Resources and Administration
  • Eric L. Trachtenberg, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Mark A. Glickman, Chief Commercial Officer
  • James Patrick Tursi M.D., Chief Medical Officer
  • Kenneth B. Lee Jr., Lead Independent Director
  • Neal Franklin Fowler, Independent Director

How do I buy Aralez Pharmaceuticals stock?

Shares of Aralez Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aralez Pharmaceuticals' stock price today?

One share of Aralez Pharmaceuticals stock can currently be purchased for approximately $1.41.


MarketBeat Community Rating for Aralez Pharmaceuticals (NASDAQ ARLZ)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  229
MarketBeat's community ratings are surveys of what our community members think about Aralez Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aralez Pharmaceuticals (NASDAQ:ARLZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (183.69% upside)
Consensus Price Target History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Price Target History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Analysts' Ratings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Chardan CapitalLower Price TargetBuy -> Buy$5.50 -> $4.00HighView Rating Details
4/10/2017Bloom BurtonUpgradeAccumulate -> BuyMediumView Rating Details
10/10/2016GuggenheimSet Price TargetBuy$12.00N/AView Rating Details
3/16/2016Dundee SecuritiesLower Price TargetBuy$10.00 -> $9.00N/AView Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Earnings History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017N/AView Earnings Details
8/9/20176/30/2017($0.41)($0.42)$21.37 million$27.62 millionViewListenView Earnings Details
5/9/20173/31/2017($0.40)($0.42)$20.23 million$26.00 millionViewListenView Earnings Details
3/13/201712/31/2016($0.26)($0.37)$21.86 million$20.00 millionViewListenView Earnings Details
11/7/2016Q316($0.32)($0.32)$12.23 million$136.00 millionViewListenView Earnings Details
8/9/2016Q216($0.19)($0.27)$9.70 million$12.60 millionViewListenView Earnings Details
5/10/2016Q116($0.53)($0.73)$9.70 million$8.10 millionViewListenView Earnings Details
3/15/2016Q415($0.28)($0.40)$9.25 million$5.97 millionViewListenView Earnings Details
11/9/2015Q315($0.26)($0.25)$5.20 million$5.80 millionViewListenView Earnings Details
8/10/2015Q215$0.04($0.50)$4.60 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115$0.08$0.01$4.70 million$4.40 millionViewListenView Earnings Details
3/9/2015Q414$0.17$0.21$8.55 million$9.90 millionViewListenView Earnings Details
11/6/2014Q314$0.11$0.20$7.50 million$7.50 millionViewListenView Earnings Details
8/7/2014Q214$0.05$0.09$7.10 million$7.40 millionViewListenView Earnings Details
5/8/2014Q1($0.06)$0.09$5.50 million$7.55 millionViewListenView Earnings Details
3/5/2014Q413($0.05)($0.07)$4.35 million$4.70 millionViewListenView Earnings Details
11/6/2013Q313($0.09)($0.16)$3.25 million$2.60 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.20)($0.13)$1.30 million$1.70 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.19)$1.43 million$1.40 millionViewListenView Earnings Details
3/6/2013Q4 2012($0.21)($0.20)$1.46 million$1.40 millionViewListenView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.73 million$0.90 millionViewN/AView Earnings Details
8/1/2012($0.25)($0.17)ViewN/AView Earnings Details
5/1/2012($0.28)($0.28)ViewN/AView Earnings Details
2/28/2012$2.00$2.04ViewN/AView Earnings Details
11/3/2011($0.24)($0.24)ViewN/AView Earnings Details
7/28/2011($0.19)($0.21)ViewN/AView Earnings Details
5/5/2011($0.23)($0.19)ViewN/AView Earnings Details
3/9/2011$0.56$0.61ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aralez Pharmaceuticals (NASDAQ:ARLZ)
2017 EPS Consensus Estimate: ($1.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.43)($0.43)($0.43)
Q3 20171($0.46)($0.46)($0.46)
Q4 20171($0.46)($0.46)($0.46)
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Aralez Pharmaceuticals (NASDAQ ARLZ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/21/2013special$1.7512/31/201312/11/201312/30/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 23.79%
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Insider Trades by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017James Patrick TursiInsiderSell9,960$2.50$24,900.00View SEC Filing  
7/28/2017Scott J CharlesCFOSell10,804$1.25$13,505.00View SEC Filing  
6/23/2017Eric TrachtenbergInsiderSell7,720$1.33$10,267.60View SEC Filing  
6/15/2017Arthur S KirschDirectorBuy15,000$1.15$17,250.00View SEC Filing  
6/14/2017Arthur S KirschDirectorBuy50,000$1.17$58,500.00View SEC Filing  
6/5/2017Andrew I KovenInsiderSell161,906$1.28$207,239.68View SEC Filing  
5/23/2017Jason AryehDirectorSell388,685$1.44$559,706.40View SEC Filing  
3/20/2017Andrew I KovenInsiderSell7,825$2.41$18,858.25View SEC Filing  
3/20/2017Scott J CharlesCFOSell5,205$2.41$12,544.05View SEC Filing  
3/15/2017Adrian AdamsCEOBuy500,000$2.46$1,230,000.00View SEC Filing  
3/15/2017Arthur S KirschDirectorBuy45,000$2.27$102,150.00View SEC Filing  
3/15/2017James Patrick TursiInsiderBuy4,750$2.11$10,022.50View SEC Filing  
11/29/2016Robert Paul HarrisDirectorSell104,778$4.99$522,842.22View SEC Filing  
11/28/2016Robert Paul HarrisDirectorSell20,000$4.65$93,000.00View SEC Filing  
11/14/2016Kenneth B Lee JrDirectorBuy1,000$4.95$4,950.00View SEC Filing  
11/11/2016Seth RudnickDirectorBuy30,000$4.77$143,100.00View SEC Filing  
9/15/2016Robert Paul HarrisDirectorSell150,000$5.82$873,000.00View SEC Filing  
5/20/2016James Patrick TursiInsiderBuy10,000$3.75$37,500.00View SEC Filing  
5/16/2016Eric TrachtenbergInsiderBuy10,000$3.76$37,600.00View SEC Filing  
5/13/2016Kenneth B Lee JrDirectorBuy1,000$3.50$3,500.00View SEC Filing  
5/12/2016Andrew I KovenInsiderBuy71,500$3.49$249,535.00View SEC Filing  
5/12/2016Arthur S KirschDirectorBuy27,500$3.49$95,975.00View SEC Filing  
5/12/2016Scott J CharlesCFOBuy50,000$3.49$174,500.00View SEC Filing  
12/3/2015John R PlachetkaMajor ShareholderSell23,479$8.14$191,119.06View SEC Filing  
11/13/2015John R PlachetkaMajor ShareholderSell150,000$7.00$1,050,000.00View SEC Filing  
11/12/2015Adrian AdamsCEOBuy1,000,000$6.55$6,550,000.00View SEC Filing  
9/10/2015John E. BarnhardtVPSell18,322$8.78$160,867.16View SEC Filing  
6/18/2015John G FortInsiderSell78,905$10.93$862,431.65View SEC Filing  
6/3/2015Gilda Marie ThomasInsiderSell23,555$7.53$177,369.15View SEC Filing  
4/15/2015Gilda Marie ThomasInsiderSell25,000$8.61$215,250.00View SEC Filing  
3/17/2015Gilda Marie ThomasInsiderSell50,000$7.51$375,500.00View SEC Filing  
1/2/2015Gilda Marie ThomasVPSell25,000$7.91$197,750.00View SEC Filing  
12/1/2014Par Investment Partners LpMajor ShareholderBuy500,000$7.50$3,750,000.00View SEC Filing  
11/18/2014John R PlachetkaCEOSell50,000$9.00$450,000.00View SEC Filing  
11/6/2014John R PlachetkaCEOSell50,000$9.08$454,000.00View SEC Filing  
10/9/2014John R PlachetkaCEOSell50,000$8.12$406,000.00View SEC Filing  
10/8/2014John R PlachetkaCEOSell32,227$8.16$262,972.32View SEC Filing  
9/30/2014John R PlachetkaCEOSell50,000$7.48$374,000.00View SEC Filing  
9/29/2014John R PlachetkaCEOSell38,298$7.53$288,383.94View SEC Filing  
9/15/2014Dennis L McnamaraEVPSell4,275$7.85$33,558.75View SEC Filing  
9/9/2014John R PlachetkaCEOSell50,000$8.24$412,000.00View SEC Filing  
9/8/2014John R PlachetkaCEOSell30,000$8.30$249,000.00View SEC Filing  
8/25/2014John E BarnhardtVPSell4,293$8.25$35,417.25View SEC Filing  
8/20/2014John R PlachetkaCEOSell50,000$7.78$389,000.00View SEC Filing  
8/8/2014John R PlachetkaCEOSell50,000$7.75$387,500.00View SEC Filing  
7/30/2014John R PlachetkaCEOSell50,000$7.34$367,000.00View SEC Filing  
7/9/2014John R PlachetkaCEOSell50,000$8.88$444,000.00View SEC Filing  
7/8/2014John R PlachetkaCEOSell33,551$8.87$297,597.37View SEC Filing  
7/2/2014William L HodgesCFOSell11,414$9.05$103,296.70View SEC Filing  
6/23/2014John E BarnhardtVPSell27,484$8.80$241,859.20View SEC Filing  
6/23/2014William L HodgesCFOSell5,688$9.05$51,476.40View SEC Filing  
6/20/2014William L HodgesCFOSell50,000$9.05$452,500.00View SEC Filing  
6/19/2014William L HodgesCFOSell9,516$9.05$86,119.80View SEC Filing  
6/17/2014William L HodgesCFOSell112,156$9.03$1,012,768.68View SEC Filing  
6/16/2014Dennis L McnamaraEVPSell15,100$9.06$136,806.00View SEC Filing  
6/11/2014Arthur S KirschDirectorSell9,430$9.30$87,699.00View SEC Filing  
6/5/2014Arthur S KirschDirectorSell2,500$8.67$21,675.00View SEC Filing  
6/2/2014Arthur S KirschDirectorSell2,500$8.73$21,825.00View SEC Filing  
5/27/2014Arthur S KirschDirectorSell10,000$8.38$83,800.00View SEC Filing  
5/22/2014John BarnhardtVPSell77,840$8.31$646,850.40View SEC Filing  
5/16/2014John FortInsiderSell4,000$8.49$33,960.00View SEC Filing  
5/16/2014William HodgesCFOSell71,003$8.16$579,384.48View SEC Filing  
4/24/2014John FortInsiderSell13,725$9.61$131,897.25View SEC Filing  
12/20/2013John FortInsiderSell22,500$9.63$216,675.00View SEC Filing  
7/17/2013Par Investment Partners LpMajor ShareholderBuy90,000$5.25$472,500.00View SEC Filing  
12/27/2012John E BarnhardtVPSell5,219$5.25$27,399.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Latest Headlines for Aralez Pharmaceuticals (NASDAQ:ARLZ)
Source:
Loading headlines, please wait.

Social

Chart

Aralez Pharmaceuticals (ARLZ) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.